EGFR and non-small cell lung carcinoma: Studies have demonstrated that the sequence of targeted therapy versus immunotherapy is associated with the incidence of irAEs: one study included 126 NSCLC patients with EGFR mutations who were treated with ICI and EGFR TKIs.